No Data
Stock Movement | TOT BIOPHARMA-B (01875) Surges Over 9% Intraday as Wuxi XDC CEO Jonathan Li Takes Over as Executive Director and Board Chairman
Topyou Pharmaceutical-B (01875) surged over 9% intraday. As of the time of writing, it was up 6.77%, trading at HKD 4.89 with a turnover of HKD 19.571 million.
Topyou Pharmaceutical-B (01875) has appointed Li Jincan as Executive Director and Chairman of the Board.
Topyo Pharma-B (01875) announced that, effective April 29, 2026, Mr. Fu Shan has resigned as an executive director, chairman of the board, and member and chairperson of the Nomination Committee and Strategy & ESG Committee; Dr. Liu Weidong has resigned as a non-executive director and member of the Audit and Related Party Transactions Review Committee and Strategy & ESG Committee; Ms. Sun Hui has resigned as an independent non-executive director, member and chairperson of the Audit and Related Party Transactions Review Committee, and member of the Nomination Committee; Mr. Zhang Qing has resigned as an independent non-executive director, member of the Audit and Related Party Transactions Review Committee, and member and chairperson of the Remuneration Committee; and Dr. Gu Xuelin has resigned as an independent non-executive director and member of the Remuneration Committee, Nomination Committee, and Strategy & ESG Committee.
Express News | Biodlink International Co Ltd - Mr. Shan Fu Resigns as Executive Director and Chairperson of Board
BIODLINK-B: Annual Report 2025
WUXI XDC Gains Majority Control of TOT BIOPHARM After Cash Offers Close
Topyou Pharmaceutical demonstrates strong performance as the company transitions to become a leading CDMO enterprise, with expectations of higher order prices in the future.
Towardys Pharma-B (01875) surged nearly 12% at one point in the afternoon trading session. As of the time of writing, it was up 11.62%, trading at HKD 5.86, with a turnover of HKD 24.7414 million.